The concern with AbbVie’s blockbuster biologic Humira is the lost of patent exclusivity in the U.S. and Europe over the next two years. The worry is revenue from Humira will drop off a cliff as generic drugs enter the market…. Read More
There is a common misconception with AbbVie (ABBV) in regards to its blockbuster drug Humira. Sure Dividend outlines this misconception below. That’s where the risk with AbbVClie comes in. The company’s composition-of-matter patent for Humira expires at the end of… Read More
AMM Third Quarter 2019 Client Letter “History doesn’t repeat itself, but it often rhymes.” – Attributed to Mark Twain This summer marks the 20th